Search Results
Sep 09, 2026, 07:30 ET Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
intrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing
More news about: Kazia Therapeutics Limited
Sep 09, 2026, 02:00 ET Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
SEATTLE and HAMBURG, Germany, Sept. 9, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses,
More news about: Evotec SE
Sep 04, 2026, 11:00 ET Emdoor Information Strengthens ODM Customization for Rugged Computing Solutions
workflows and information sharing.Complex projects progress through five key stages: Product Initiation, Engineering Validation Test (EVT), Design Validation Test (DVT), Production Validation Test (PVT), and Mass Production (MP). Each stage has defined validation requirements and deliverables,
More news about: Emdoor Information
Sep 02, 2026, 02:04 ET Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
HALLBERGMOOS, Germany, Sept. 2, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses
More news about: Evotec SE
Sep 01, 2026, 07:30 ET Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
intrinsic pontine glioma in August 2020 and for atypical teratoid/rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing
More news about: Kazia Therapeutics Limited
Sep 01, 2026, 07:15 ET Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
intrinsic pontine glioma in August 2020 and for atypical teratoid/rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing
More news about: Kazia Therapeutics Limited
Aug 31, 2026, 17:58 ET Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
intrinsic pontine glioma in August 2020 and for atypical teratoid/rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing
More news about: Kazia Therapeutics Limited
Aug 28, 2026, 07:30 ET Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
intrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 16:09 ET Kazia Therapeutics Limited Announces Proposed Public Offering
intrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 16:01 ET Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
intrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing
More news about: Kazia Therapeutics Limited
Aug 06, 2026, 02:16 ET Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
HAMBURG, Germany, Aug. 6, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. (NASDAQ: ODTX) to discover potential new treatments
More news about: Evotec SE
Jul 30, 2026, 07:00 ET Basking Biosciences Announces Publication Showing BB-031 Restores Blood Flow in a Microfluidic Model of Acute Ischemic Stroke (AIS)
Importantly, clots formed in the model reproduced the clot composition reported in human samples from patients who have undergone endovascular thrombectomy (EVT). These include fibrin, platelets, and vWF, supporting the model as a relevant system for studying arterial thrombosis and treatment."These findings
More news about: Basking Biosciences Inc.
Jul 22, 2026, 15:25 ET Research Reveals Persistent Racial Disparities in Stroke Treatment and Outcomes
teaching hospitals between 2018 and 2022. They found that Black patients were less likely than white patients to receive endovascular thrombectomy (EVT), a minimally invasive procedure used to remove blood clots from blocked arteries in the brain.The disparity existed across all levels of stroke
More news about: Society of NeuroInterventional Surgery
Jul 13, 2026, 15:43 ET Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
HAMBURG, Germany, July 13, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook. Full financial
More news about: Evotec SE
Jun 30, 2026, 02:16 ET Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
SEATTLE and HAMBURG, Germany, June 30, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy
More news about: Evotec SE
Jun 11, 2026, 12:02 ET Evotec Reports Results of the Annual General Meeting 2026
HAMBURG, Germany, June 11, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting.All agenda items put to vote were adopted by the Company's shareholders
More news about: Evotec SE
Jun 02, 2026, 07:30 ET Kazia Therapeutics Appoints James Levine as Chief Financial Officer
intrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing
More news about: Kazia Therapeutics Limited
May 26, 2026, 07:30 ET Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
intrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing
More news about: Kazia Therapeutics Limited
Apr 15, 2026, 09:10 ET Alibaba's Amap Set to Unveil First Embodied Robot, Homegrown Model Tops Global Rankings
state-of-the-art performance across seven international benchmarks in embodied navigation — including CityWalker, SocNav, R2R-CE, RxR-CE, HM3D-OVON, BridgeNav and EVT-Bench — giving it a commanding lead over rivals in the field.Amap said in a statement: "We have been deeply engaged in embodied intelligence,
More news about: Amap
Apr 15, 2026, 08:00 ET Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing
More news about: Kazia Therapeutics Limited
Apr 13, 2026, 17:05 ET Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing
More news about: Kazia Therapeutics Limited
Mar 17, 2026, 09:01 ET Archive360 and EVT Partner to Automate Retention Compliance Using Enterprise Data and AI Governance
Magic Quadrants for Digital Communications Governance & Archiving and Structured Data Archiving & Application Retirement.About EVTEVT is a strategic technology partner for global enterprises operating in highly regulated environments. The company provides a comprehensive suite
More news about: Archive360
Mar 09, 2026, 09:15 ET Telit Cinterion Expands Next-Generation GNSS Portfolio with New Dual-Band Modules for Scalable IoT Positioning
applications that require continuous, ultraprecise positioning. It also preserves design continuity for our customers."Engineering validation testing (EVT) samples of the SE873K5-D are available now. Design validation testing (DVT) samples are expected soon. Mass production is planned for Q2 2026.Design
More news about: Telit Cinterion
Mar 05, 2026, 08:00 ET Revalesio to Present Advances in Stroke Treatment with RNS60 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
RESCUE trial evaluating RNS60 in participants with acute ischemic stroke undergoing EVT within 12 hours since stroke onset. The analysis demonstrated that participants treated with high-dose RNS60 plus EVT versus EVT alone experienced:4.8 days earlier discharge from the hospital
More news about: Revalesio Corporation
Mar 04, 2026, 09:00 ET Join Outsmart 2026 To Discover How Visier Workforce AI Is Bringing the Future of Work Into Enterprises Now
events.visier.com/evt-outsmart-2026About VisierVisier is the global leader in Workforce Intelligence, empowering organizations to make every people
More news about: Visier